Insmed, Inc.
INSM Healthcare Biotechnology
Insmed, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $606.4 million, up 66.7% from fiscal 2024. In the quarter to June 2026, revenue grew 296.1%, EPS grew 96.5%, free cash flow grew 54.5% and total debt was flat, each against the same quarter a year earlier. Revenue growth for five consecutive years.
Follow INSM
Insmed, Inc. (INSM) EV/Sales
As of 16 October 2026, Insmed, Inc. (INSM) trades at a EV/Sales of 18.1×. Over the past ten years it has ranged from 0.0× (March 2019) to 98.1× (December 2025); the current reading is higher than 69% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 56.1× | 81.32% |
| FY2024 | 30.9× | 104.29% |
| FY2023 | 15.1× | 56.24% |
| FY2022 | 9.7× | (37.66%) |
| FY2021 | 15.5× | (17.62%) |
| FY2020 | 18.9× | 35.48% |
| FY2019 | 13.9× | — |
| FY2018 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 20.0× | (52.79%) |
| Mar 2026 | 42.5× | (24.26%) |
| Dec 2025 | 56.1× | (15.35%) |
| Sep 2025 | 66.2× | 46.62% |
| 26 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| BNTX BioNTech SE Sponsored ADR compare | 1.8× |
| INCY Incyte Corporation compare | 3.1× |
| JAZZ Jazz Pharmaceuticals PLC compare | 3.4× |
| ALNY Alnylam Pharmaceuticals, Inc. compare | 6.0× |
| EXEL Exelixis, Inc. compare | 6.1× |
| GMAB Genmab A/S Sponsored ADR compare | 6.4× |
| ASND Ascendis Pharma A/S compare | 11.6× |
| INSM Insmed, Inc. | 18.1× |
| ROIV Roivant Sciences Ltd. compare | 2,742× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)